This webinar focuses on how high content analysis (HCA) is used in phenotypic target and drug discovery for early identification of compounds that do not have adverse physiological effects. Therapeutic areas highlighted include oncology, CNS and fibrosis.

The target discovery platform described combines adenoviral shRNA libraries (SilenceSelect®) to modulate gene function in primary cell-based phenotypic assays with high-throughput imaging and analysis. Similarly, to assess the effect of small molecules in cell-based assays mimicking complex multifactorial diseases, high-content imaging allows the combined analysis of several phenotypic readout parameters.


  • Rhea van de Bospoort, PhD, Team Leader, Biology, Charles River